• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

It's the first drug shown to slow Alzheimer's. Why is it off to a slow start? | AP News


<



















The field is in complete shambles…no clear hierarchy within accounts. Inexperienced reps trying to communicate very complex strategies within academic IDNs looks bad for Eisai. Overlays hired with NO EXPERIENCE IN PHARMA!!!! Eisai at its best
 








The field is in complete shambles…no clear hierarchy within accounts. Inexperienced reps trying to communicate very complex strategies within academic IDNs looks bad for Eisai. Overlays hired with NO EXPERIENCE IN PHARMA!!!! Eisai at its best

The Japs always think they can get by on the cheap and on the quick. There are so many moving parts ro this launch that a top tier, well-resourced company would have a hard time pulling it off. Spoiler alert: Eisai isn’t a top tier company.